Actuate Therapeutics

cancer target detection radiopharma radio
Biotech

Actuate's pancreatic cancer drug boosts survival by 3 months

Actuate has set its sights on getting elraglusib approved for pancreatic cancer after the GSK-3β drug showed a three-month survival increase.
James Waldron Jun 2, 2025 7:30am
Photo of Wall Street street sign with american flags in the background

Actuate is latest biotech on Nasdaq after $22.4M IPO

Aug 15, 2024 4:29am
IPO initial public offering markets raise financing

Cancer-focused Actuate makes 2nd tweak to IPO plans in a week

Jul 24, 2024 4:37am
calculator calculate budget

Actuate halves IPO to $22M, scales back clinical plans

Jul 22, 2024 4:54am
Photo of Wall Street street sign with american flags in the background

Actuate unveils modest $50M IPO to fund cancer drug trials

Jul 17, 2024 4:45am
IPO initial public offering markets raise financing

Clinical-stage cancer biotech Actuate latest to eye summer IPO

May 28, 2024 9:45am